GGrantIndex
← Leaderboards

Inviragen, Inc.

Fort Collins, CO

Compare ↔
$19,388,880
Total funding
8
Grants

Funding over time

peak $4.7M · FY200613
$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13

Funding mix

By agency

NIH$19,388,880 · 8

By mechanism

N01$11,030,342 · 1
U01$2,873,420 · 1
R44$2,828,772 · 1
R43$2,067,991 · 4
R41$588,355 · 1

Investigators at Inviragen, Inc.

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

Not enough data

Largest grants

Development of Technologies to Facilitate the Use of and Response to Vaccines$4,654,902
N01 · FY2012 · AI
Development of Technologies to Facilitate the Use of and Response to Vaccines$3,183,629
N01 · FY2013 · AI
Development of Technologies to Facilitate the Use of and Response to Vaccines$1,833,080
N01 · FY2010 · AI
Development of Technologies to Facilitate the Use of and Response to Vaccines$1,358,731
N01 · FY2011 · AI
Preclinical development of a chimeric tetravalent dengue vaccine$1,195,165
U01 · FY2007 · AI
Clinical Development of Combination Plague/Smallpox Vaccine$999,900
R44 · FY2010 · AI
Clinical Development of Combination Plague/Smallpox Vaccine$979,594
R44 · FY2009 · AI
Clinical Development of Combination Plague/Smallpox Vaccine$849,278
R44 · FY2011 · AI
Preclinical development of a chimeric tetravalent dengue vaccine$771,968
U01 · FY2008 · AI
Preclinical development of a chimeric tetravalent dengue vaccine$487,622
U01 · FY2009 · AI
Preclinical development of a chimeric tetravalent dengue vaccine$418,665
U01 · FY2006 · AI
Multivalent HPV Capsomere Vaccines$373,315
R43 · FY2008 · CA
Mucosal modified vaccinina Ankara-based plaque vaccines$357,558
R43 · FY2006 · AI
Mucosal modified vaccinina Ankara-based plaque vaccines$309,521
R43 · FY2007 · AI
Second Generation Dengue Vaccine$299,993
R43 · FY2010 · AI
Second Generation Dengue Vaccine$299,977
R43 · FY2009 · AI
MVA-based vaccines against highly pathogenic avian influenza$299,702
R41 · FY2007 · AI
MVA-based vaccines against highly pathogenic avian influenza$288,653
R41 · FY2008 · AI
Development of a Novel, Chimeric Chikungunya Vaccine$208,896
R43 · FY2008 · AI
Development of a Novel, Chimeric Chikungunya Vaccine$202,027
R43 · FY2009 · AI